This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. ESPR, ACTU, DERM, HURA, ACIU, LXRX, ALDX, KRRO, PRQR, and TNGXShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Esperion Therapeutics (ESPR), Actuate Therapeutics (ACTU), Journey Medical (DERM), TuHURA Biosciences (HURA), AC Immune (ACIU), Lexicon Pharmaceuticals (LXRX), Aldeyra Therapeutics (ALDX), Korro Bio (KRRO), ProQR Therapeutics (PRQR), and Tango Therapeutics (TNGX). These companies are all part of the "medical" sector. Vital Therapies vs. Esperion Therapeutics Actuate Therapeutics Journey Medical TuHURA Biosciences AC Immune Lexicon Pharmaceuticals Aldeyra Therapeutics Korro Bio ProQR Therapeutics Tango Therapeutics Vital Therapies (NASDAQ:VTL) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Does the media refer more to VTL or ESPR? In the previous week, Esperion Therapeutics had 17 more articles in the media than Vital Therapies. MarketBeat recorded 17 mentions for Esperion Therapeutics and 0 mentions for Vital Therapies. Esperion Therapeutics' average media sentiment score of 0.72 beat Vital Therapies' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Vital Therapies Neutral Esperion Therapeutics Positive Which has higher valuation and earnings, VTL or ESPR? Vital Therapies has higher earnings, but lower revenue than Esperion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/AEsperion Therapeutics$332.31M0.65-$209.25M-$0.25-4.36 Does the MarketBeat Community believe in VTL or ESPR? Esperion Therapeutics received 261 more outperform votes than Vital Therapies when rated by MarketBeat users. However, 74.40% of users gave Vital Therapies an outperform vote while only 70.23% of users gave Esperion Therapeutics an outperform vote. CompanyUnderperformOutperformVital TherapiesOutperform Votes36974.40% Underperform Votes12725.60% Esperion TherapeuticsOutperform Votes63070.23% Underperform Votes26729.77% Do institutionals & insiders hold more shares of VTL or ESPR? 15.5% of Vital Therapies shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 33.9% of Vital Therapies shares are held by company insiders. Comparatively, 1.0% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is VTL or ESPR more profitable? Vital Therapies has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% Esperion Therapeutics -29.37%N/A -10.77% Which has more volatility and risk, VTL or ESPR? Vital Therapies has a beta of 3.51, indicating that its stock price is 251% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Do analysts prefer VTL or ESPR? Esperion Therapeutics has a consensus target price of $6.42, suggesting a potential upside of 488.69%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Vital Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryEsperion Therapeutics beats Vital Therapies on 10 of the 15 factors compared between the two stocks. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.73M$6.85B$5.56B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E RatioN/A7.4422.6918.83Price / SalesN/A257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book3.976.576.794.33Net Income-$41.47M$143.14M$3.22B$247.97M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$1.15-1.7%N/A-12.0%$48.73MN/A0.0010ESPREsperion Therapeutics3.478 of 5 stars$0.91-1.4%$6.42+607.2%-47.1%$179.78M$332.31M-1.42200Upcoming EarningsAnalyst RevisionNews CoverageGap UpACTUActuate TherapeuticsN/A$9.05+1.1%$20.50+126.5%N/A$176.77MN/A0.0010DERMJourney Medical2.6939 of 5 stars$7.58+1.5%$9.88+30.3%+93.7%$175.13M$56.13M-8.0690Short Interest ↑News CoverageHURATuHURA BiosciencesN/A$3.97-3.2%$12.67+219.1%N/A$173.41MN/A0.00N/APositive NewsACIUAC Immune2.3029 of 5 stars$1.70+3.7%$12.00+605.9%-29.5%$170.70M$27.31M-3.70140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsLXRXLexicon Pharmaceuticals3.3117 of 5 stars$0.69-2.9%$3.67+432.9%-60.0%$169.41M$31.08M-0.92140ALDXAldeyra Therapeutics2.3975 of 5 stars$2.76+3.8%$9.67+250.2%-33.3%$164.80MN/A-2.9415Short Interest ↑KRROKorro Bio1.6206 of 5 stars$17.47-3.4%$120.43+589.3%-64.1%$164.03M$2.27M-1.8670Analyst UpgradeAnalyst RevisionNews CoveragePRQRProQR Therapeutics2.9465 of 5 stars$1.54+7.7%$9.50+516.9%+0.0%$162.03M$18.91M-4.81180Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTNGXTango Therapeutics2.3751 of 5 stars$1.49+2.1%$12.33+727.7%-80.1%$161.08M$42.07M-1.2690Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies ESPR Competitors ACTU Competitors DERM Competitors HURA Competitors ACIU Competitors LXRX Competitors ALDX Competitors KRRO Competitors PRQR Competitors TNGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTL Stock Free VTL Stock Alerts